Leadership team.

As Global President of Inizio Ignite, Remco leads the Inizio Ignite leadership team in facilitating continued growth globally, connecting the organization’s expertise to drive results for clients and create a positive impact on patients. Remco joined Putnam, a strategy consulting firm and part of Inizio Ignite, in 2000, spending the first 12 years as a strategic advisor to several top 20 biopharma companies. After becoming a Partner in 2012, Remco supported the growth of the firm from a small boutique to one of the leading global life science strategy consultancies. In 2019, Remco became the CEO of Putnam and supported the team in driving strong organic growth and managing strategically relevant acquisitions to make the firm what it is today – a strong 400+ team and leading advisory organization for the life sciences.

Emma has deep experience supporting organizations across the utilities, public and private sectors to deliver strategic projects and large-scale transformation programs. Prior to her current role as COO, Emma led Strategy & Special Projects, responsible for driving all aspects of the Inizio Ignite strategy and bringing initiatives to life. Emma also led the organization’s change program. Prior to joining Inizio, Emma was a Director of EY's People Consulting business and held the position of Chief of Staff for Ireland Consulting. Prior to joining EY, Emma also worked with Accenture Management Consulting.

Jeff Dill is the Group President of Innovation & Growth for Inizio Ignite. Prior to his current role, Jeff served as the CEO of Vynamic, a leading healthcare industry management consulting company helping innovative clients in the US, UK, and Europe achieve actionable strategy, operational intelligence, and healthy culture. With over 20 years of experience in consulting, Jeff started his career at Accenture and joined Vynamic in 2005 – inspired by their purpose: We Believe There Is A Better Way. Jeff is driven by his professional passion for ‘TACT’ - Transparency, Awareness, Clarity, and Trust - and has used this approach to clear communications to create a better experience for Vynamic team members and the clients they serve. Key elements of the healthy corporate culture Jeff leads have been featured on CNBC and The Wall Street Journal.

As President of Putnam, Matt Riordan leads a team that combines strategic acuity with a mission to advance patient impact. Since stepping into his leadership role at Putnam, he has sought to advance a culture that values rigorous thinking, inclusive teaming, and purposeful execution. He has focused investments in developing people alongside next generation AI platforms and scaling new offerings so clients benefit from sharp frameworks, modern analytics, and field-tested playbooks. Over his 20+ year career at Putnam he has partnered with leading biopharma organizations across therapeutic areas and stages, from pipeline shaping to global launch, bringing structured thinking, objective analysis, and an operator’s bias for results. Matt has helped evolve Putnam’s capabilities and culture, defined by apprenticeship, high standards, and collaborative problem solving. His hallmark is turning complex market signals into clear decisions: what to build, where to invest, and how to win. He believes the best strategies are both analytically sound and eminently executable, and he pushes teams to close the gap between insight and outcome. A lifelong learner and teacher, Matt has lectured at Harvard’s GSAS and holds a BA from Boston College and an MBA from Yale.

With broad experience in the pharmaceutical industry spanning over more than 25 years, Dermot joined STEM as CEO in November 2021. As Group President of STEM & Research Partnership, Dermot is responsible for driving growth and innovation for the businesses. Prior to joining STEM, Dermot spent 5 years at Novartis in the Clinical Development arena, first leading a major transformation in clinical data operations and then leading the broader clinical technology and innovation function. In this role, Dermot had responsibility for the support, oversight and evolution of Novartis’ end-to-end clinical technology platform and for driving digitization and innovation in the execution of clinical trials.

As President of Vynamic, Haben Debessay leads efforts to shape the future of healthcare through bold, strategic change. With more than two decades of experience in consulting and operational leadership, Haben helps clients and teams connect vision to execution—translating complex challenges into transformative outcomes that advance business performance. Prior to his current role, Haben served as Chief Operating Officer at Vynamic, where he led global consulting operations and guided the firm’s growth across the U.S. and U.K. His leadership emphasized operational excellence, empowered teams, and an unwavering focus on delivering extraordinary results for clients. Earlier in his career, Haben held leadership roles at KPMG Advisory in both their Risk and Management Consulting groups. He holds both an MBA and BSBA in Finance from the University of Delaware. Haben believes true transformation happens when clarity, purpose, and people align to unlock what’s next for the healthcare industry.

112

Aman heads the India consulting team. His experience and core focus is artificial intelligence, big data, analytics consulting, data strategy, and productization. Prior to joining Putnam and Inizio in 2020, he led the analytics operations of the San Francisco headquartered AI consulting firm Absolutdata. He founded AI & analytics at the startup RocSearch as its CEO and headed the Analytics consulting practice as Director at Protiviti. He started his strategy career at Andersen Consulting. Aman studied and received his MBA from IIM-Ahmedabad. Before that, he attained an Integrated Master’s and Bachelor’s degree in Biochemical Engineering and Biotechnology from IIT-Delhi.